NCT01716806 2024-06-11A Study of Brentuximab Vedotin With Hodgkin Lymphoma (HL) and CD30-expressing Peripheral T-cell Lymphoma (PTCL)Seagen Inc.Phase 2 Completed131 enrolled 28 charts
NCT02663518 2024-05-10A Trial of PF-07901800 (TTI-621) for Patients With Hematologic Malignancies and Selected Solid TumorsPfizerPhase 1 Terminated249 enrolled 43 charts